Moderna and Mitsubishi Tanabe Partner for mRNA Vaccine Promotion in Japan

Moderna and Mitsubishi Tanabe Pharma Corporation have announced a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio in Japan, which includes the COVID-19 vaccine, Spikevax. Under this agreement, Moderna will be responsible for the manufacturing, sales, medical education, and distribution of its mRNA respiratory vaccines. Both companies will work together to ensure widespread access to Moderna’s mRNA respiratory vaccines to maximize public health benefits in Japan. The agreement is set to run initially until March 31, 2029, with no financial terms disclosed.

Kazumasa Nagayama, President and Representative Director of Moderna Japan, expressed pleasure in partnering with Mitsubishi Tanabe Pharma to commercialize their COVID-19 vaccine and future mRNA respiratory vaccines in Japan. He noted Mitsubishi Tanabe Pharma’s significant heritage and extensive experience in public health and vaccines in Japan. Nagayama emphasized the ongoing public health threat posed by COVID-19 and the importance of their collaboration. Akihiro Tsujimura, Representative Director of Mitsubishi Tanabe Pharma, highlighted Moderna’s global impact with its COVID-19 vaccines since the pandemic's onset. He expressed delight in collaborating with Moderna on the commercial activities for the COVID-19 vaccine and other mRNA respiratory vaccines in Japan, reiterating their commitment to contributing to public health through their vaccine business.